Roundhill Glp-1 & Weight Loss ETF(OZEM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$28.76
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OZEM

11/20/2026: OZEM (1-star) is currently NOT-A-BUY. Pass it for now.

The Roundhill Glp-1 & Weight Loss ETF (OZEM) provides targeted, actively managed exposure to global companies spearheading weight management and anti-obesity therapeutics. Its main strengths include pioneering thematic access and active management flexibility, though it carries notable concentration risks in top holdings like Eli Lilly and Novo Nordisk. It functions best as a satellite growth allocation for investors seeking specific exposure to the obesity treatment boom. Key risks involve high valuation multiples, regulatory pressures, and modest trading liquidity. Investors should monitor clinical updates, insurance coverage trends, and broader pharmaceutical sentiment.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe fund targets companies experiencing hyper-growth driven by breakthrough medical treatments.
Momentum investorStrong fit while signal remains positiveMomentum can be powerful during positive clinical data releases or favorable sales reports for top holdings.
Value investorWeak fitMany underlying holdings trade at premium valuation multiples due to high growth expectations.
Dividend/Income investorWeak fitThe portfolio focuses on capital appreciation and clinical development rather than high dividend payouts.
Low-risk investorWeak fitConcentrated exposure to a handful of pharmaceutical stocks introduces high volatility and regulatory risk.

Investor Profile

Ideal Investor Profile

The ideal investor is a growth-oriented market participant seeking targeted exposure to the secular trend of weight-loss therapeutics who is comfortable with higher sector-specific volatility.

Suitability

Best suited for tactical, long-term thematic growth allocations rather than core passive holdings or short-term day trading.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighThe fund experiences sharp price swings based on pharmaceutical trial outcomes and sector sentiment.
Market riskMedium / highBroader economic downturns can affect healthcare spending and speculative growth assets.
ConcentrationHighA significant percentage of assets is concentrated in just a couple of major pharmaceutical companies like Eli Lilly and Novo Nordisk.
Tracking/expenseMediumThe 0.59% expense ratio is higher than standard passive index alternatives.
LiquidityMedium / highLower assets under management can result in wider spreads and lower daily trading volumes.
Business/sector qualityMediumSubject to intense regulatory scrutiny, clinical trial failures, and patent expirations.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

OZEM exhibits heightened historical volatility compared to broad market indices due to its specialized thematic nature and heavy reliance on a few pharmaceutical leaders.

Market Risk

Primary risks stem from clinical trial failures, regulatory setbacks, changes in drug reimbursement policies, and heavy concentration in top holdings.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Single stockEli Lilly and Company (LLY)15.28Serves as a primary pillar holding due to its dominant market position in GLP-1 treatments like Zepbound.
Single stockNovo Nordisk A/S (NVO)11.64Provides vital core exposure to the pioneer of Wegovy and Ozempic.
Single stockPfizer Inc. (PFE)7.69Offers large-cap pharmaceutical exposure as the company develops alternative pipeline obesity treatments.
Single stockKailera Therapeutics (KLRA)6.3Represents clinical-stage innovation targeting next-generation metabolic disease therapies.
Single stockCSPC Pharmaceutical Group (1093)5.37Adds international exposure via Asian pharmaceutical development in metabolic disorders.
IndustryRemaining Global Biotech and Pharma Holdings53.72Diversifies the portfolio across various global pharmaceutical firms and supply chain enablers.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit 16.85%
Avg. Invested days 56
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
ETF Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.